新辅助化疗对晚期卵巢癌患者带瘤状态、手术效果及预后的影响

目的：探讨新辅助化疗对晚期卵巢癌患者带瘤状态、手术效果及预后的影响。方法选取80例晚期卵巢癌患者，实施新辅助化疗联合减瘤术治疗的40例患者为研究组，仅实施减瘤术治疗的40例患者为对照组，比较两组临床疗效、手术效果及预后情况。结果研究组患者治疗的总有效率为87.5%（35/40），高于对照组的65.0%（26/40），差异有统计学意义（P﹤0.05）；研究组患者的腹腔积液量、术中出血量、总瘤灶直径、转移灶数均少于对照组，手术时间短于对照组，差异均有统计学意义（P﹤0.05）；研究组副损伤发生率低于对照组，最佳减灭率高于对照组，差异有统计学意义（P﹤0.05）；研究组患者的1年、3年生存率分别为92.5%（37/40）、57.5%（23/40），与对照组的90.0%（36/40）、52.5%（21/40）比较，差异均无统计学意义（P﹥0.05）；研究组中位生存时间为（42±5）个月，与对照组的（37±5）个月比较，差异无统计学意义（P﹥0.05）。结论新辅助化疗能够有效改善晚期卵巢癌患者带瘤状态、手术效果，但对预后影响不大。

Influences of neoadjuvant chemotherapy on tumor burden,surgery efficacy and prognosis in patients with advanced ovarian cancer

Objective To investigate the influences of neoadjuvant chemotherapy on the tumor burden, efficacy of surgery, and prognosis in patients with advanced ovarian cancer. Method 80 cases of advanced ovarian cancer were in-cluded in the study, 40 cases with neoadjuvant chemotherapy+cytoreductive surgery, and another 40 cases with cytore-ductive surgery alone were stratified as study group and control group, respectively. The clinical efficacy, effect of sur-gery and prognosis of the two groups were compared. Result The overall response rate in the study group was 87.5%(35/40), and was significantly higher than that of the control group at 65.0%(26/40) (P<0.05);The ascites volume, intra-operative blood loss, total diameter of tumors, number of metastatic lesions as well as the operative time in the study group were all less than the control group, with significant differences observed (P<0.05);the incidence of collateral injury was lower, and successful debulking rate was higher in the study group compared with the control group, with significant differ-ences observed (P<0.05);The 1-and 3-year survival rates in study group were 92.5%(37/40) and 57.5%(23/40), similar with those of the control group at 90.0% (36/40) and 52.5% (21/40), respectively (P> 0.05); The median survival time was (42±5) months in study group and (37±5) months in control group (P>0.05). Conclusion Neoadjuvant chemothera-py reduces tumor burden and improves surgery outcome for patients with advanced ovarian cancer, but has little effect on the prognosis.